Requis Pharmaceuticals Inc. is a new product-focused Biotech company that is developing a series of de-risked pharmaceutical and nutraceutical products based in part on the new science of tryptophan, the precursor of the central nervous system (CNS) neurotransmitter serotonin.  Serotonin is known as a universal “feel good” synaptic neurotransmitter.

Requis’ initial focus is on Sleep Disordered Breathing (SDB) in particular; lead product Requisom is being developed as a remedy for Obstructive Sleep Apnea (OSA). Sleep apnea is a highly prevalent condition affecting at least 4% of men and 2% of women; many sufferers go undiagnosed in an estimated market of over 20 M Americans. Untreated OSA is associated with increased cerebrovascular, cardiovascular (CV) and cancer morbidity and sudden death.

The company invents, develops and then seeks out-licensing partners for commercially attractive pharmaceutical and consumer health products for US and worldwide markets. Requis Pharma has filed a series of US/PCT patent applications; four of them are now published; it proactively seeks IP protection on all its products.  ​Requis is the French word for “required” and Latin for sleep is “somnum” – so Requisom = “required for sleep”. Requis is now executing a focused plan to drive its compelling new products into the marketplace.